Note: Ingredients listed on restricted chemical lists
General Information
Revision date
2014-01-29
Product name
PRELUDE TERMITICIDE; PRELUDE 240
CAS No.
52645-53-1
1.2.1 Relevant identified uses
888-462-6822 TRANSPORTATION (24 HOURS)
Manufacturer Name
AMVAC CHEMICAL CORPORATION
Emergency telephone
888-462-6822
Icons in SDS
Company Information
company name
AMVAC CHEMICAL CORPORATION
Section 2
SECTION 2: Hazards identification
EMERGENCY OVERVIEW: CAUTION! Harmful if swallowed, inhaled or absorbed through the skin. May cause eye irritation. May cause skin irritation. Do not get in eyes, on skin, or on clothing. Avoid breathing vapors or spray mist. Use with adequate ventilation. Do not contaminate feed or foodstuffs. KEEP OUT OF REACH OF CHILDREN. Highly toxic to fish and aquatic organisms.
Principle Routes of Exposure
Ingestion, inhalation, eye contact, and skin contact SIGNS OF ACUTE OVEREXPOSURE: A person suffering from acute exposure to Permethrin may suffer from mild eye irritation. In addition, exposure to Permethrin may induce adverse effects on the nervous system. Exposure to the vapors can cause irritation to eyes, lungs, and mucous membranes. Contact with liquid can cause eye irritation, skin irritation such as itching, tingling, burning or numbness, and skin defatting. Ingestion may result in vomiting. Aspiration (breathing) of the vomitus into the lungs must be avoided as even small quantities may result in aspiration pneumonitis (pneumonia). Prolonged exposure to aromatic hydrocarbons may result in congestive effects to a wide variety of internal organs. Symptoms of overexposure include tremors, convulsions, unsteady gait, hypersensitivity, salivation and nasal discharge. Other possible signs of overexposure include facial erythema (flushing) and facial skin tingling. SIGNS OF CHRONIC OVEREXPOSURE: Same as acute. OTHER POTENTIAL HEALTH EFFECTS: No evidence of mutagenic or teratogenic potential has been observed. EPA (2004) has evaluated the carcinogenic potential of Permethrin under its ‘Review Draft of the Guidelines fro Carcinogen Risk Assessment (1999)’. Permethrin has suggestive evidence of carcinogenicity but not sufficient to assess human carcinogenic potential. IARC has classified Permethrin as a Group 3 (sufficient animal evidence) carcinogen.
Medical Conditions Generally Aggravated by Exposure
Dermatitis, asthma-like conditions, other CNS related diseases. CARE SHOULD BE EXERCISED IN HANDLING THIS FORMULATION.
